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Summary An immunotoxin (IT) comprising abrin A chain attached to the mouse monoclonal antibody SWAl 1, recognising a cell surface antigen highly associated with human small cell lung cancer (SCLC), was
synthesised using a hindered disulphide crosslinker, N-succinimidyl 3-(2-pyridyldithio) butyrate (SPDB), and
purified by Blue Sepharose CL-6B affinity chromatography. The IT preparation contained monomeric con- jugate, composed of one abrin A chain molecule linked to one SWAlI1 molecule, and was free from
unconjugated A chain or antibody. The IT fully retained the cell-binding capacity of the antibody component and the ribosome-inactivating activity of the A chain. In cytotoxicity assays using the SW2 SCLC cell line in tissue culture, SWA I-SPDB-abrin A chain inhibited the incorporation of 3H-leucine by 50% at a concentra- tion of 10 pM and by 99% at a concentration of 1 nM. The anti-tumour efficacy of the IT was tested in nude mice bearing established s.c. solid SW2 tumour xenografts. A single i.v. injection of SWAll-SPDB-abrin A
chain at a non-toxic dose induced a significant 7 to 10 day growth delay that could not be matched by administration of equivalent doses of either unconjugated SWA or abrin A chain alone. The results of this study indicate that the antigen recognised by SWA is an effective target for therapy of SCLC with A chain ITs in vivo.
The first trials of systemic immunotoxin (IT) therapy in
cancer employed monoclonal antibody (Mab) conjugates
comprising native glycosylated ricin A chain attached to the
antibody by means of a simple disulphide linkage (reviewed
by Wawrzynczak, 1991). Three innovations in IT production
have been introduced to improve IT efficacy. Firstly, the use
of toxin A chains that lack oligosaccharide side-chains or
that contain chemically-modified carbohydrate structures to
prevent liver entrapment (Thorpe et al., 1988; Wawrzynczak
et al., 1990a, 1991a). Secondly, the use of hindered disulphide
linkages to increase IT stability in the circulation (Worrell et
al., 1986; Thorpe et al., 1988). Thirdly, the affinity purifi-
cation of IT by Blue Sepharose chromatography to remove
unconjugated antibody (Knowles & Thorpe, 1987).
The A chain of the toxin abrin, which resembles ricin in
structure and mode of action, possesses properties that make
it attractive for the construction of therapeutic ITs. Firstly,
abrin A chain occurs naturally in a form devoid of side-chain
glycosylation and consequently abrin A chain ITs are subject
to only a low level of hepatic uptake in vivo (Olsnes et al.,
1975; Skilleter et al., 1989). Secondly, abrin A chain ITs have
a greater intrinsic resistance to breakdown in vitro and in vivo
than ricin A chain ITs (Wawrzynczak et al., 1990a). Thirdly,
abrin A chain forms ITs with a potency matching or exceed-
ing that of analogous ITs made using ricin A chain (For-
rester et al., 1984; Blakey et al., 1987; Sivam et al., 1987).
Lastly, abrin A chain ITs have demonstrated significant anti-
tumour effects in animal models of lymphoma and metastatic
cancer (Hwang et al., 1984; Blakey et al., 1987; Thorpe et al.,
1987).
The mouse Mab SWA11, recognising a cell-surface antigen
highly associated with human small cell lung cancer (SCLC),
has been shown to localise efficiently in xenografts of the
SCLC cell line SW2 in nude mice (Smith et al., 1989; 1990;
1991) and to form A chain ITs with selective toxic activity
against several SCLC cell lines in tissue culture (Wawrzync-
zak et al., 1990b; 1991b). In this study, we have synthesised,
affinity purified, and fully characterised an IT consisting of
abrin A chain attached to SWA 11 via a hindered disulphide
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crosslink. We report the cytotoxic effects of the IT against
the SW2 cell line in tissue culture and demonstrate its ability
to delay the growth of established SW2 solid tumour xeno-
grafts in nude mice.
Materials and methods
Synthesis andpurification ofimmunotoxins
SWAI 1 (mouse IgG2a) was purified from hybridoma super-
natant as described by Smith et al. (1989). Abrin A chain was
purified from the native abrin toxin as described by Wawrzy- nczak et al. (1990a). N-succinimidyl-3-(2-pyridyldithio) buty-
rate (SPDB) was synthesised according to Worrell et al.
(1986).
SWA1 l-SPDB-abrin A chain was synthesised following the
basic methodology described by Cumber et al. (1985) with a
number of important modifications. SWAI1 (50 mg) was
subjected to affinity chromatography on a column (50 cm x
1.6 cm i.d.) of Blue Sepharose CL-6B equilibrated with
50 mM sodium phosphate buffer, pH 7.5 (Knowles & Thorpe, 1987). The antibody that eluted from the column amounted
to 94% of the total amount applied. The small fraction of
Mab retained on the column was removed with phosphate buffer containing 2 M NaCl. The main SWAl1 fraction was
concentrated to about 10 ml and applied to a column
(90 cm x 2.6 cm i.d.) of Sephacryl S200HR equilibrated with
20 mm sodium phosphate, 0.1 M NaCI, pH 7.5, to isolate the
main monomeric Mab fraction from a small amount of
aggregated material eluting at the void volume of the col-
umn. The pre-purified SWAl1 (30mg) was reacted with a
2.5-fold molar excess of SPDB to introduce an average of 1.0
S-pyridyl groups per Mab molecule, mixed with a 2.5-fold
molar excess of freshly reduced abrin A chain, concentrated
and allowed to stand at room temperature for 24 h and at
4°C for a further 24 h. The reaction mixture was then sub-
jected to Sephacryl S200HR chromatography under the con-
ditions described above to separate the fraction containing IT
and unconjugated Mab from the unreacted A chain. The
IT-containing fraction was then concentrated, dialysed into
50 mM sodium phosphate buffer, pH 7.5, and applied to the
Blue Sepharose column which had been re-equilibrated with
the same buffer. The unconjugated Mab was allowed to elute
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from the column. The IT fraction, all of which bound to the
column, was removed with phosphate buffer containing 1 M
NaCl, concentrated, and dialysed into phosphate-buffered
saline (PBS). The final preparation of SWAl l-SPDB-abrin A
chain at a concentation of 0.50 mg IT ml-' was sterilised by
filtration, aliquoted into sterile Nunc vials in a laminar flow
cabinet, frozen rapidly in liquid N2, and stored at - 70°C.
An IT comprising abrin A chain conjugated to SWAl 1 via
the conventional unhindered disulphide crosslinker N-succini-
midyl 3-(2-pyridyldithio) propionate (SPDP) was prepared as
described previously (Forrester et al., 1984; Wawrzynczak et
al., 1990b).
Molecular properties ofSWAII-SPDB-abrin A chain
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis
(SDS-PAGE) and gel permeation high performance liquid
chromatography (HPLC) were performed as described previ-
ously (Wawrzynczak et al., 1990a).
Ribosome-inactivating activity was determined using a
rabbit reticulocyte lysate assay similar to that described by
Forrester et al. (1984). Samples of IT or abrin toxin were
pre-treated with 2-mercaptoethanol at a final concentration
of 0.2 M for 1 h at 37°C to generate free A chain for the
assay.
Cell-binding ability was measured by indirect immunofluo-
rescence essentially as described by Derbyshire and Wawrzyn-
czak (1991). Briefly, a total of 1 x 106 SW2 cells, preincubated
with IT or unconjugated SWAl1 at various concentrations
on ice, were treated with anti-mouse Ig, fluorescein-linked
whole antibody from sheep and analysed by flow cytometry.
Cytotoxic effects ofimmunotoxins
Cytotoxic activity against the SW2 cell line in tissue culture
was determined essentially as described by Wawrzynczak et
al. (1990b). Briefly, dilutions of ITs or other agents were
added to microtitre wells containing a total of 2 x 104 SW2
cells in suspension and incubated for 48 h. 3H-Leucine
(1 pCi) was added to each culture followed by incubation for
a further 24 h, harvesting of cells, and measurement of cell-
incorporated radioactivity by scintillation counting.
Toxicity ofSWAII-SPDB-abrin A chain to nude mice
Male nu/nu mice received a single i.p. injection of the sterile
stock solution of SWAI1-SPDB-abrin A chain at each of
four doses, 15, 30, 60 and 120fig IT per mouse, or abrin A
chain at 100, 200, 400 and 800fg per mouse. The animals
were monitored at intervals for evidence of toxic signs and
weight loss, and were killed painlessly at the onset of mori-
bundity. The mean weight of the mice at the start of the
experiment were 19.3 g ( ± 0.8 g) and 18.8 g (± 1.3 g) for the
groups treated with the IT and A chain respectively. The
LD50 doses were calculated according to Weil (1952).
Therapy experiments in nude mice
Stock solutions of SWA1 1-SPDB-abrin A chain, SWA11 and
abrin A chain in PBS were prepared for injection by dilution
under sterile conditions. The final solutions contained IT at a
concentration of 90Atg ml-1, Mab at 75jig ml-' and A chain
at 15tLg ml-'. S-carboxymethylated bovine serum albumin
was included at 0.5 mg ml - as a carrier protein.
Groups of 6 to 8 nu/nu mice were implanted s.c. in one
flank with a suspension of 1 x 107 SW2 cells from tissue
culture. After approximately 2 to 3 weeks when tumours
became palpable, each mouse received a single i.v. injection
of 0.1 ml solution containing (i) IT, (ii) unconjugated Mab,
(iii) unconjugated A chain, or (iv) carrier protein only.
Tumour growth was monitored by measuring the two largest
perpendicular diameters and calculating tumour volume ac-
cording to the formula:
V = d'.D.n
6
where d and D are the shorter and longer diameters respec-
tively.
Results
Molecular properties ofSWAJI -SPDB-abrin A chain
The affinity-purified preparation of SWAI1-SPDB-abrin A
chain migrated on SDS-PAGE predominantly as a single
band having a lower mobility than that of the unmodified
SWAl1 antibody (Figure 1). This electrophoretic behaviour
was consistent with that expected of a conjugate comprised
of a single molecule of abrin A chain (30 kDa) covalently
linked to a single molecule of SWAl1 (150 kDa). The IT
preparation eluted from a gel permeation HPLC column as a
single sharp peak with an elution time slightly shorter than
that of SWA 11 itself (Figure 2). The elution time was consis-
tent with the expected molecular mass of monomeric IT
(180 kDa). The preparation was entirely free of aggregated
protein which would have eluted at the void volume of the
column.
The ability of SWAll-SPDB-abrin A chain to associate
with live SW2 cells was determined by indirect immunofluo-
rescence and flow cytometry (Figure 3). Both the IT and
unconjugated SWAl1 bound to the cells in similar amounts
at corresponding concentrations of Mab indicating that the
binding ability of the Mab had not been significantly dimin-
ished by attachment of the A chain. The IT also retained the
full ribosome-inactivating activity of the conjugated abrin A
chain. Following reduction to generate the free A chain, the
IT preparation had identical catalytic activity in a cell-free
assay to native abrin toxin at equimolar concentration
(Figure 4).
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Figure 1 SDS-PAGE of SWAI1-SPDB-abrin A chain. Samples
were run on a 4-12.5% polyacrylamide gradient gel run under
non-reducing conditions. Protein bands were visualised by
Coomassie Blue staining. Lane 1, SWAl1 Mab (5fJg); lane 2,
SWAI1-SPDB-abrin A chain (1O0 g).IMMUNOTOXIN FOR THERAPY OF HUMAN SMALL CELL LUNG CANCER 363
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Figure 2 Gel permeation HPLC of SWAl 1-SPDB-abrin A
chain. A sample (17.5fg) of SWAll-SPDB-abrin A chain was
applied to a column (75 cm x 0.75 cm i.d.) of TSK-G3000SW
equilibrated with 20 mM sodium phosphate, 0.1 M sodium sul-
phate, pH 6.8 containing 0.05% (w/v) sodium azide at a flow rate
of 0.04 ml min-'. The elution positions of marker proteins of
known molecular mass (kDa) are shown.
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Figure 4 Ribosome-inactivating activity of SWAll-SPDB-abrin
A chain. The effects of different concentrations of reduced
SWAlI-SPDB-abrin A chain (0) and abrin (U) upon protein
synthesis by a rabbit reticulocyte lysate were determined by
measuring the inhibition of 3H-leucine incorporated into TCA-
precipitable protein relative to untreated incubations.
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Figure 3 Cell-binding ability of SWAlI-SPDB-abrin A chain.
SW2 cells exposed to different concentrations of SWAll-SPDB-
abrin A chain (e) or unconjugated SWAl1 (A) were treated
with flourescein-linked anti-mouse Ig and the cell-associated
fluorescence was measured by flow cytometry.
Cytotoxic effects ofSWAIJ-SPDB-abrin A chain
SWA 11-SPDB-abrin A chain caused a concentration-depen-
dent inhibition of 3H-leucine incorporation by SW2 cells in
tissue culture. The results of a representative experiment are
shown in Figure 5. The concentration at which 3H-leucine
incorporation was inhibited by 50% (IC50) was 1.2 ± 0.6 x
10-11 M (mean and standard deviation calculated from three
separate experiments). At an IT concentration of 1 x 10' M,
3H-leucine incorporation was decreased to less than 1% of
that by untreated cells. The cytotoxic activity of the IT made
with the hindred disulphide linker did not differ significantly
from that of an analogous IT made with the standard unhin-
dered linker, SWAlI-SPDE-abrin A chain, which had an
IC50 of 0.8 ± 0.6 x 101-X M. SWA11-SPDB-abrin A chain was
approximately 220-fold less toxic than abrin, with an IC50 of
5.4 ± 1.7 x 10-14 M and 160-fold more potent than uncon-
jugated abrin A chain which had an IC50 of 1.9 ± 1.4 x
10-9 M. Unconjugated SWA 1I had no cytotoxic effects on
SW2 cells at a concentration of 1 x 10-7 M. In control
10-14 10-13 10-12 10-11 110 i0-9 1o-8
Concentration of A chain (M)
Figure 5 Cytotoxic effects of SWAI l-SPDB-abrin A chain. SW2
cells in tissue culture were treated with SWA11-SPDB-abrin A
chain (0), SWA1l-SPDP-abrin A chain (0) abrin (U), and
abrin A chain (0) at the concentrations shown. The effects on
protein synthesis were judged from the amount of 3H-leucine
incorporated by treated cells relative to that by parallel untreated
cultures (>60,000 c.p.m.). Each point represents the mean of
quadruplicate determinations. Error bars denote the standard
deviations from the mean values except where smaller than the
symbol used.
experiments with the human T-lymphoblastoid cell line
CEM, which does not express the antigen recognised by
SWAIl, the SWAlI-SPDB-abrin A chain IT was no more
toxic than unconjugated abrin A chain (not shown).
Toxicities ofSWAII-SPDB-abrin A chain and abrin A chain
The toxicity of SWAIl-SPDB-abrin A chain to nude mice
was determined by administering a single i.p. injection of
sterile IT solution to mice at different doses. Mice treated
with 15 tLg of IT showed no evidence of ill effects or weight
loss. At the 30jig dose of IT, the mice showed a significant
weight loss after 5 days with recovery after 9 days. An
immediate and severe weight loss (>25% after 9 days) was
observed in mice receiving 60 tLg of IT; one mouse recovered
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2000- and developed a peritoneal ascites. At the 120 ,g dose level,
both mice lost weight immediately and did not survive
beyond 2 days after IT administration. The LD_0 was cal-
culated to be 3.12 mg of IT per kg animal weight equivalent
to 0.52 mg ofconjugated A chain per kg. Similar toxic effects
were observed with unconjugated abrin A chain. The LD50
dose of abrin A chain was estimated to be 20.7 mg per kg.
1000
Anti-tumour effects ofSWAJI-SPDB-abrin A chain
Nude mice bearing established SW2 solid tumour xenografts
were treated by a single i.v. injection of SWAI1I-SPDB-abrin
A chain containing 9ytg of IT (50 pmoles) equivalent to
approximately 15% of the LD50 dose determined by i.p.
administration of IT. Control groups of mice received equiv-
alent doses ofunconjugated abrin A chain (1.5jig), of uncon-
jugated SWA 11 (7.5fig), or of the carrier protein solution
alone. Treatment of mice with these agents at the doses
stated produced no weight losses or other signs of toxicity.
The effects of the treatments on tumour growth were moni-
tored by measuring the relative increase in tumour volume
(Figure 6a). Tumour growth was not inhibited by abrin A
chain alone compared to the treatment with carrier solution
or untreated controls (omitted for clarity). The SWA 11 Mab
alone gave a slight tumour growth delay of 2 days although
this was not significantly different from the growth of
tumours in mice receiving abrin A chain. In contrast,
tumour-bearing mice treated with SWA1 1-SPDB-abrin A
chain demonstrated a growth delay of 7 days relative to
those treated with abrin A chain only which was significant
by Student's t-test (P = 0.05-0.02).
For the groups of tumour-bearing mice treated with the IT
or the A chain, the mean tumour volumes at the time of
injection were 114 ± 37 mm3 and 116 ± 26 mm3 respectively.
Analysis of the data for the three mice in each of these two
groups bearing the smallest tumours, 55 ± 4 mm3 and
54±9 mm3 for the IT and A chain respectively, revealed a
more pronounced anti-tumour effect (Figure 6b). Tumour-
bearing mice treated with IT showed no increase in tumour
size in the 7 days following IT injection and a significant
(P = 0.05-0.02) tumour growth delay averaging 10 days.
In a further experiment, tumour-bearing mice were treated
with a single i.v. injection of carrier-free abrin A chain at a
dose of 3.1 mg kg-' equivalent to 15% of the LD50 dose
determined by i.p. administration of A chain. There was no
significant difference in the growth rate of SW2 xenografts
between groups of mice receiving the A chain or diluent
alone.
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Figure 6 Anti-tumour effects ofSWAI1I-SPDB-abrin A chain. a,
Nude mice bearing established s.c. SW2 tumours received a single
i.v. injection on day 0 of 9jig SWA1l-SPDB-abrin A chain (@),
7.5jLg SWAll (A) or 1.5jig abrin A chain (0). Tumour dia-
meters were measured at intervals following injection and the
results were plotted as the percentage increase in tumour volume
relative to the tumour volume at day 0. Error bars denote the
standard deviations from the mean values. b, Experimental data
for mice with tumours approximately 55 mm3 in volume on day
0.
Discussion
In this study, we have demonstrated the synthesis and puri-
fication of an IT designed for therapy of human SCLC which
incorporates the aglycosyl abrin A chain linked via a hin-
dered disulphide crosslinker SPDB to a mouse Mab SWAl
recognising an antigen highly associated with SCLC. The
purified IT had a defined molecular composition correspond-
ing to a 1:1 conjugate of SWAl1 and abrin A chain. The
chromatographic properties of the IT in solution were consis-
tent with those of a monomeric globular protein of the
expected molecular mass. SWA11-SPDB-abrin A chain fully
retained the cell-binding capacity of the Mab and the ribo-
some-inactivating activity of the A chain. The IT exerted
potent and selective toxic effects against the SW2 cell line in
tissue culture and significantly delayed the growth of estab-
lished SW2 tumour xenografts in nude mice treated with a
single non-toxic dose.
The cytotoxic activity of SWA 1 -SPDB-abrin A chain was
indistinguishable from that of an analogous IT made with
the unhindered SPDP crosslinking reagent. This result was in
accord with previous findings that increasing the resistance of
the disulphide bond between Mab and A chain to chemical
reduction had no deleterious effect upon IT activity (Worrell
et al., 1986; Thorpe et al., 1988). The cytotoxic activity of the
two SWAl1-abrin A chain ITs was found to be identical to
that of an analogous SWAl1-SPDP-ricin A chain IT in
parallel assays whereas abrin toxin and unconjugated abrin A
chain were approximately 5-fold more toxic to the SW2 cell
line than ricin and ricin A chain respectively (Derbyshire et
al., unpublished results). This suggests that the cytotoxic
potency of the cell-binding ITs in this system was determined
by the antigen-dependent route of entry into the target cell
rather than by the inherent properties of the A chain.
The toxicity to nude mice of abrin A chain was increased
by about 40-fold following conjugation to the SWAl1 Mab
via the SPDB crosslinker. The higher toxicity of the IT
reflects, at least in part, the prolonged serum half-life of the
abrin A chain coupled to Mab compared with the uncon-
jugated A chain which is cleared rapidly from the blood-
stream (Wawrzynczak et al., 1990a). Model studies have
shown that both the abrin A chain and the hindered disul-
phide crosslinker contribute to the stability of this type of IT
to reduction by glutathione (Cumber et al., unpublished
results). The toxicity of abrin A chain ITs has not previously
been reported but, in another study, the attachment of degly-
cosylated ricin A chain to a Mab via a different hindered
crosslinker resulted in only a 7-fold increase in its toxicity to
normal Balb/c mice (Thorpe et al., 1988). This apparent
difference in toxicity could have a number of causes: firstly, if
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level leading to greater exposure of normal tissues; secondly,
if the abrin A chain IT interacted preferentially with some
essential normal tissue; thirdly, if strains of mice differed in
their susceptibility to intoxication. These uncertainties can
best be addressed in future by direct comparison of the
pharmacokinetics, biodistribution and toxicities of abrin A
chain and deglycosylated ricin A chain ITs made with the
same Mab and crosslinker.
The anti-tumour efficacy of SWA11-SPDB-abrin A chain
was tested in nude mice bearing established s.c. solid tumours
derived from the SW2 human SCLC cell line. A single i.v.
injection of the IT at a non-toxic dose induced a delay in
tumour growth that could not be matched by unconjugated
SWAI1 or abrin A chain. The largest anti-tumour effects in
the xenograft model were observed in the mice bearing the
smallest tumours at the time of injection suggesting that such
anti-SCLC ITs may be most effective against small tumour
deposits and metastases present at an early stage in the
disease or following reduction of tumour bulk by chemo-
therapy. The anti-tumour effects were modest given that the
antigen recognised by SWA 11 is highly expressed on the
SW2 cell line (>99.9% cells positive by indirect immuno-
fluorescence), that the pattern of antigen expression is highly
similar between SW2 cells in tissue culture and in xenografts,
and that SWA 11-A chain ITs can selectively eliminate
>99.9% of clonogenic SW2 cells in culture (Derbyshire et
al., unpublished results; Zangemeister-Wittke et al., unpub-
lished results). Further studies will aim to determine whether
tumour progression resulted from the outgrowth of target
antigen-negative or IT-resistant cells or from failure to erad-
icate target antigen-positive cells because of insufficient IT
penetration, and to define the optimal dosing schedules for
achieving maximal anti-tumour effects.
In summary, we have demonstrated that a selectively cyto-
toxic SWAl1-abrin A chain IT made with a hindered disul-
phide crosslinker was capable of inducing a significant delay
in the growth of a solid SCLC tumour xenograft in a nude
mouse model at a single non-toxic dose. This is the first
report describing the anti-tumour effects of an anti-SCLC A
chain IT in vivo. The findings of this study have two major
implications. Firstly, abrin A chain appears to be highly
suitable for the production of therapeutic ITs. The cloning of
the abrin gene and the demonstration of the expression ofthe
A chain from Escherichia coli in catalytically active form
(Wood et al., 1991) will permit the further optimisation of
the properties of abrin A chain ITs. Secondly, the antigen
recognised by the SWAl1 Mab is an effective target for
therapy of SCLC with A chain ITs. This antigen has recently
been cloned and characterised (Waibel et al., unpublished
results) enhancing the prospect of developing second genera-
tion anti-SCLC ITs with greater activity and selectivity.
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